Brian Johnson, thanks for being here. >> Yeah, it's good to see you. >> How are you feeling.Maybe just share with us what you did a few days ago. And >> yeah, I did um a I did five MOD DMT, which is the most powerful psychedelic on the planet. Uh it's somewhere between five and 10 times more powerful than DMT.And so, yeah, I it's so it's been 48 hours. I'm still learning how to talk about it. >> You know what.Many of the biggest tech CEOs and VCs have in common. They sleep on the Pod by eight sleep. It's be ...

Core Viewpoint - NRx Pharmaceuticals has appointed Prof. Joshua C. Brown as Chief Medical Innovation Officer to enhance its drug development program focused on treating PTSD and depression in military personnel, veterans, and first responders [1][5]. Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD [7]. - The company is working on NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation for treating suicidal ideation in depression [7]. Appointment of Prof. Joshua C. Brown - Prof. Brown is a psychiatrist, neurologist, and neuroscientist with significant expertise in Transcranial Magnetic Stimulation (TMS) and neuroplastic medications [2][3]. - He has over $20 million in federal funding for TMS research and holds a position at Harvard Medical School [2]. - His role at NRx will involve collaboration with Dr. Dennis McBride to advance TMS as a therapy for combat-related depression and PTSD [3]. Research and Development Focus - NRx has filed an Investigational New Drug application with the FDA to test a combination therapy involving ketamine, TMS, and NRX-101 in its HOPE Therapeutics clinic network [4]. - Recent evidence indicates a high return-to-duty rate among first responders with PTSD treated with ketamine, TMS, and hyperbaric oxygen [4]. Strategic Vision - Prof. Brown emphasizes the importance of academic-industry partnerships to bridge the gap between scientific discovery and real-world application, particularly in addressing the rising burden of depression, anxiety, PTSD, and suicide [6]. - NRx is committed to translating TMS-pharmacologic augmentation strategies into effective treatments for patients suffering from serious brain disorders [6].

Company Overview - NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD [4] - The company is developing NRX-101, which has been designated as an FDA Breakthrough Therapy for suicidal treatment-resistant bipolar depression, with plans to file a New Drug Application (NDA) for Accelerated Approval [4] Recent Developments - NRx Pharmaceuticals has filed an Abbreviated New Drug Application (ANDA) for NRX-100, a preservative-free IV ketamine, for currently approved indications [5] - The company has initiated an NDA filing for NRX-100 for the treatment of suicidal depression, based on clinical trial results and new data from French health authorities [5] - NRx has received Fast Track Designation from the US FDA for the development of NRX-100 to treat patients with acute suicidality and has filed a patent for this novel formulation [5] Events and Collaborations - The CEO and Chairman of NRx Pharmaceuticals will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on July 29-30, 2025, discussing neuroplasticity in CNS disorder treatments [1][2] - The discussion will include insights from Prof. Samuel Wilkinson, a pioneer in the understanding of ketamine and other neuroplastic drugs for treating depression and PTSD [2] Subsidiary Information - HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, is establishing a network of interventional psychiatry clinics to provide ketamine and other therapies for suicidal depression and related disorders [6]

Health & Wellness Benefits - Strength training helps combat age-related muscle loss, which typically starts between 30 and 40 years old at a rate of approximately 1% per year [1] - Strength training can improve mental and psychological well-being, potentially reducing anxiety and depression [2][15] - Building muscle through strength training has preventative health benefits, including cancer and heart disease prevention, and lowering inflammation levels [11] - Strength training increases bone density, reducing the risk of osteoporosis, unlike high levels of cardio which can decrease bone density [12] - Strength training elevates brain-derived neurotrophic factor (BDNF), improving brain health, memory, concentration, and attention, and potentially lowering the risk of Alzheimer's and dementia [12][13][14][15] Psychological Resilience - Resistance training can be viewed as resilience training, fostering consciousness, control, and confidence [16][17] - Strength training promotes a growth mindset by encouraging curiosity and the willingness to challenge perceived limits [18] Practical Application - The industry encourages incorporating strength training using various methods, including body weight exercises, dumbbells, or even household items [19] - The industry suggests that the mental fortitude gained from strength training can be applied to manage stress and challenges in daily life [9][10][16]